medical weight loss programs

$38.4 Billion U.S. Commercial Weight Loss Market Pivots To Survive GLP-1 Drugs Explosion

March 24, 2025 Marketdata LLC has just published a new report: “The U.S. Weight Loss Market: Commercial (non-medical) Programs & Products”, March 2025. This is a 220-page analysis of commercial weight loss programs/companies and how they have been affected by and respond to the onslaught of the GLP-1 drugs competition. The $38 billion U.S. commercial weight loss […]

$38.4 Billion U.S. Commercial Weight Loss Market Pivots To Survive GLP-1 Drugs Explosion Read More »

FDA Says No More Compounded Weight Loss Drugs – Industry OFA Appeal Shot Down

News / John LaRosa

March 14, 2025 On Mar. 5, a judge denied a request from the Outsourcing Facilities Association (OFA), an industry group for compounding pharmacies, to block the FDA’s attempt to stop the production of compounded tirzepatide. Generally, making copies of brand-name drugs is not legal until their patents expire. But there are exceptions: Compounding pharmacies can

FDA Says No More Compounded Weight Loss Drugs – Industry OFA Appeal Shot Down Read More »

Recession Is Coming – But Commercial Diet Companies Could Benefit

News / John LaRosa

March 13, 2025 Marketdata, the parent company of DietBusinessWatch.com, is currently updating its report on the Commercial & Retail Weight Loss Market. Several things have become apparent as we do the research Marketdata analysts see a possible opportunity this year for the commercial (non-medical) weight loss firms to recover some ground. Here’s how we think

Recession Is Coming – But Commercial Diet Companies Could Benefit Read More »

Weight Watchers Reports Q4 and 2024 Yearly Results

News / John LaRosa

Feb. 27, 2025 WW reported its Q4 and full year 2024 results today. The company’s Board of Directors named Interim President and CEO Tara Comonte, to a permanent role as President and CEO, effective February 26, 2025. “We are pleased with the momentum in our Clinical business in the Fourth Quarter, reflecting the increasing demand

Weight Watchers Reports Q4 and 2024 Yearly Results Read More »

$33 Billion U.S. Medical Weight Loss Market Dominated by GLP-1 Drugs – New Report

News / John LaRosa

Feb. 27, 2025 Marketdata LLC has published anew 154-page analysis of the U.S. weight loss market, entitled: “The U.S. Medical Weight Loss Market: The Impact of GLP-1 Drugs on Doctors, Hospitals, Clinics and Franchises”, February 2025. This report presents a complete picture of the medical weight loss market in the United States, with the inter-relationships between competing

$33 Billion U.S. Medical Weight Loss Market Dominated by GLP-1 Drugs – New Report Read More »

Eli Lilly To Lower Price of Zepbound Vials, GLP-1 Shortage Is Over

News / John LaRosa

Feb. 25, 2025 Eli Lilly said today that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells, as the pharma giant seeks to draw patients away from cheap, compounded copies of weight loss medications. Zepbound was originally sold in injectable pens at

Eli Lilly To Lower Price of Zepbound Vials, GLP-1 Shortage Is Over Read More »

Medifast Reports Q4 and Full Year 2024 Results

News / John LaRosa

Feb. 18, 2025 “This past year was a pivotal year for Medifast, as we continued to transform our business to meet the changing nature of a health and wellness market that has been revolutionized by the rising acceptance of GLP-1 medications,” said Dan Chard, Chairman & CEO. Fourth quarter 2024 revenue decreased 37.7% to $119.0

Medifast Reports Q4 and Full Year 2024 Results Read More »

Conflicts in Trump Administration For Support of GLP-1 Meds

Uncategorized / John LaRosa

Feb. 3, 2025 Support for the wildly popular weight loss meds in the new administration appears to be a question mark. Dr. Oz has publicly praised GLP-1s for their benefits, even pitching them on TV and social media channels, according to a Dec. 30 report from The Hill. On the other hand, Mr. Kennedy expressed

Conflicts in Trump Administration For Support of GLP-1 Meds Read More »

Zepbound Beats Wegovy for Weight Loss

News / John LaRosa

Dec. 4, 2024 StatNews.com today reported that…. Eli Lilly’s drug Zepbound resulted in weight loss that was 47% greater than the weight loss achieved with Wegovy, the rival medicine made by Novo Nordisk, according to a new head-to-head study out this morning. The news likely will not be entirely surprising to the physicians and scientists

Zepbound Beats Wegovy for Weight Loss Read More »

GLP-1 Drugs Market Update

News / John LaRosa

Sept. 23, 2024 According to Becker’s Hospital Review… On Sept. 24, Novo Nordisk CEO Lars Fruergaard Jørgensen is slated to testify at a Senate committee hearing about the costs for Wegovy and Ozempic. The hearing comes after months of disagreements between Denmark-based Novo Nordisk and the Senate Committee on Health, Education, Labor and Pensions. The

GLP-1 Drugs Market Update Read More »

(813) 971-8080